Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 39
Filtrar
1.
Appl Opt ; 55(13): 3456-61, 2016 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-27140356

RESUMO

Hamiltonian-based ray-tracing technique with mesh representation is presented for designing large-scale cloaking devices with three-dimensional arbitrary shapes, which have inhomogeneity and anisotropy in their electric permittivity and magnetic permeability. In order to deal with arbitrary shapes, the surfaces of the cloaking devices are represented by triangular meshes. Comparison between the result of cloaking simulations with the mesh representation and those with the rigorous function representation is presented. The numerical results showed that fine-mesh resolution is required for accurate evaluation of cloaking performances.

2.
Dig Liver Dis ; 44(8): 649-54, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22542605

RESUMO

BACKGROUND: 6-Mercaptopurine is often used as maintenance therapy in patients with Crohn's disease. However, toxicities like myelosuppression limit its clinical benefit. AIMS: To evaluate the efficacy of elemental diet versus 6-mercaptopurine as maintenance therapy in Crohn's disease. METHODS: Ninety-five eligible patients with Crohn's disease activity index ≤150 were randomly assigned to: 6-mercaptopurine (0.5-1.5mg/kg/day, n=30); Elental as an elemental diet (≥900 kcal/day, n=32); none (control, n=33). In the three groups, patients were and remained on 5-aminosalicylic acid (2250-3000 mg/day). Patients were observed for 2 years and the rate of relapse (Crohn's disease activity index ≥200) was monitored. RESULTS: At 24 months, the fractions of patients who had maintained remission were 60%, 46.9% and 27.2% for 6-mercaptopurine, Elental and the control groups, respectively. Log-rank test showed better efficacy for 6-mercaptopurine (P=0.0041) and Elental (P=0.0348) versus control. No significant difference was found between 6-mercaptopurine and Elental. Further, in the 6-mercaptopurine group, 2 patients experienced liver injury and one developed alopecia. CONCLUSIONS: This 24 months comparison study showed that Elental as maintenance therapy in Crohn's disease patients was as effective as 6-mercaptopurine. Elental should be useful for long-term maintenance therapy in Crohn's disease. This is the first comparison study evaluating nutritional therapy versus 6-mercaptopurine.


Assuntos
Doença de Crohn/dietoterapia , Doença de Crohn/tratamento farmacológico , Alimentos Formulados , Imunossupressores/uso terapêutico , Mercaptopurina/uso terapêutico , Adulto , Anti-Inflamatórios não Esteroides/uso terapêutico , Alimentos Formulados/efeitos adversos , Humanos , Imunossupressores/efeitos adversos , Estimativa de Kaplan-Meier , Estudos Longitudinais , Quimioterapia de Manutenção , Masculino , Mercaptopurina/efeitos adversos , Mesalamina/uso terapêutico , Recidiva , Adulto Jovem
3.
Clin Gastroenterol Hepatol ; 10(8): 879-885.e2, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22542748

RESUMO

BACKGROUND & AIMS: Low doses of aspirin can injure the gastric mucosa. It is not clear whether other drugs such as the antiplatelet agent clopidogrel also cause gastric mucosal injury or exacerbate aspirin-induced injury, or whether proton pump inhibitors prevent damage. METHODS: Twenty Japanese subjects with different CYP2C19 genotypes were randomly assigned to groups that were given a low dose of aspirin (100 mg; A), clopidogrel (75 mg; C), low dose of aspirin and clopidogrel (AC), or low dose of aspirin in combination with clopidogrel and rabeprazole (10 mg; ACR) once daily for 7 days. Subjects underwent gastroduodenoscopy and platelet tests on days 3 and 7; gastric mucosal damage was assessed by using the modified Lanza score (MLS). We performed 24-hour intragastric pH monitoring on day 7 of each regimen. We also analyzed the effects of the AC regimen on 30 patients with different CYP2C19 genotypes. RESULTS: Subjects in groups A, C, and AC had significantly higher levels of gastric mucosal damage on days 3 and 7, compared with baseline. The median MLS for the AC group was similar to that of the A group. Helicobacter pylori-negative subjects in the ACR group with different CYP2C19 genotypes had significant differences in MLS, intragastric pH, and platelet function. Gastric mucosal injury was inhibited equally among H pylori-positive subjects in the ACR group. Rabeprazole did not appear to affect platelet function or intragastric pH in subjects given clopidogrel. CONCLUSIONS: Clopidogrel and low doses of aspirin cause a similar degree of gastric mucosal damage. Rabeprazole prevented this damage without reducing the antiplatelet function of clopidogrel. However, its prophylactic effect varies with CYP2C19 genotype in H pylori-negative subjects.


Assuntos
2-Piridinilmetilsulfinilbenzimidazóis/administração & dosagem , Antiulcerosos/administração & dosagem , Hidrocarboneto de Aril Hidroxilases/genética , Aspirina/efeitos adversos , Mucosa Gástrica/patologia , Úlcera Péptica/prevenção & controle , Ticlopidina/análogos & derivados , Adulto , Povo Asiático , Aspirina/administração & dosagem , Clopidogrel , Estudos Cross-Over , Citocromo P-450 CYP2C19 , Endoscopia Gastrointestinal , Feminino , Genótipo , Humanos , Masculino , Rabeprazol , Índice de Gravidade de Doença , Ticlopidina/administração & dosagem , Ticlopidina/efeitos adversos , Resultado do Tratamento , Adulto Jovem
4.
Gan To Kagaku Ryoho ; 39(1): 81-4, 2012 Jan.
Artigo em Japonês | MEDLINE | ID: mdl-22241356

RESUMO

To investigate the effect clinical path of cancer pain treatments for opioid naive patients has on physician practice, a prepost quasi-experimental study was performed. The primary outcome measure was the percentage of patients who received 'recommended pain treatments' during the study periods. We determined the treatment to be the treatment of choice, if the physician 1) ordered a rescue dose, 2) prescribed a laxative, and 3) prescribed antiemetics when starting opioids. The secondary outcome measure was the number of newly consulted patients for our palliative care team. The end-points were measured before and after disseminating the clinical path. The rate of patients receiving recommended pain treatments significantly increased after disseminating the clinical path(p=0.03): 17%(33/18)to 61%(19/31). Patients who received a rescue order, laxative, or antiemetic when starting opioids were: 44% vs. 68%, 77% vs. 90%, and 66% vs. 77%, respectively. The number of patients newly consulting the palliative care team was increased(21 cases to 42 cases/4 month). In conclusion, the clinical path of cancer pain treatments is useful for improving the physician's practice when starting opioids for cancer pain, and might contribute to enhancing palliative care team availability.


Assuntos
Analgésicos Opioides/administração & dosagem , Procedimentos Clínicos/normas , Oxicodona/administração & dosagem , Dor/tratamento farmacológico , Cuidados Paliativos , Analgésicos Opioides/efeitos adversos , Analgésicos Opioides/uso terapêutico , Feminino , Humanos , Masculino , Oxicodona/efeitos adversos , Oxicodona/uso terapêutico
5.
J Surg Res ; 169(2): e137-43, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-21612793

RESUMO

BACKGROUND: Gastric cancer is one of the major causes of death in Japan. We have previously reported, using biopsy specimens, the usefulness of the 1064 nm near-infrared multichannel Raman spectroscopy (RAS) system as a novel diagnostic modality for gastric cancer. However, our study might not have reflected in vivo use of RAS due to a lack of tissue other than the mucosal layer in the biopsy specimens. Here, we used RAS ex vivo for optical diagnosis of gastric cancer in surgically resected stomach. MATERIALS AND METHODS: A total of 213 Raman spectra were obtained from 12 cancer lesions and their corresponding non-neoplastic areas in 10 stomachs following resection for gastric cancer. To develop optical diagnostic systems for gastric cancer, principal component analysis (PCA) of all the Raman spectra was performed. RESULTS: The averaged Raman spectra of the cancer lesions could be distinguished from those of the non-neoplastic regions. Discrimination analysis of cancer from non-neoplastic regions with 10 principal components revealed that sensitivity, specificity, and accuracy of cancer diagnosis were 73%, 73%, and 72%, respectively. RAS discriminated between differentiated and undifferentiated cancers, early and advanced cancers, as well as T1a (M) and T1b (SM) cancers with high accuracy (98%, 93%, and 98%, respectively). CONCLUSIONS: The 1064 nm near-infrared multichannel RAS system is useful not only for gastric cancer detection, but also for discrimination between differentiated and undifferentiated, as well as early and advanced cancers. RAS could help establish indications for endoscopic treatment by eliminating cancer lesions with an undifferentiated component or submucosal invasion.


Assuntos
Adenocarcinoma/diagnóstico , Espectroscopia de Luz Próxima ao Infravermelho/métodos , Análise Espectral Raman/métodos , Neoplasias Gástricas/diagnóstico , Adenocarcinoma/patologia , Adenocarcinoma/cirurgia , Idoso , Biópsia , Diferenciação Celular , Diagnóstico Diferencial , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Sensibilidade e Especificidade , Estômago/patologia , Neoplasias Gástricas/patologia , Neoplasias Gástricas/cirurgia
6.
Cancer Sci ; 102(4): 883-9, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-21244575

RESUMO

Although the main cause of gastrointestinal stromal tumor (GIST) is gain-of-function mutations in the c-kit gene in the interstitial cells of Cajal, concomitant genetic or epigenetic changes other than c-kit appear to occur in the development of metastasis. We sought to identify the genes involved in the metastatic process of gastric GIST. Microarray analysis was performed to compare gene expressions between three gastric GIST and four metastatic liver GIST. Expression levels were higher for 165 genes and lower for 146 genes in metastatic liver GIST. The upregulation of five oncogenes and downregulation of four tumor suppressor genes including versican and CD9 were confirmed by quantitative reverse transcriptional PCR. Immunohistochemistry in 117 GIST revealed that protein levels of versican and CD9 were higher and lower, respectively, in metastatic GIST. High expression of versican and low expression of CD9 in 104 primary gastric GIST correlated with poor disease-free survival (P = 0.0078 and P = 0.0018). In addition to the c-kit gene mutation, genetic or epigenetic changes other than c-kit play important roles in the metastatic process. In particular, versican and CD9 are potential prognostic markers in gastric GIST.


Assuntos
Antígenos CD/genética , Biomarcadores Tumorais/genética , Tumores do Estroma Gastrointestinal/genética , Perfilação da Expressão Gênica , Neoplasias Hepáticas/genética , Glicoproteínas de Membrana/genética , Neoplasias Gástricas/genética , Versicanas/genética , Adulto , Idoso , Antígenos CD/metabolismo , Biomarcadores Tumorais/metabolismo , Feminino , Mucosa Gástrica/metabolismo , Tumores do Estroma Gastrointestinal/metabolismo , Tumores do Estroma Gastrointestinal/patologia , Humanos , Técnicas Imunoenzimáticas , Neoplasias Hepáticas/metabolismo , Neoplasias Hepáticas/secundário , Masculino , Glicoproteínas de Membrana/metabolismo , Mutação/genética , Análise de Sequência com Séries de Oligonucleotídeos , Prognóstico , Proteínas Proto-Oncogênicas c-kit/genética , Proteínas Proto-Oncogênicas c-kit/metabolismo , RNA Mensageiro/genética , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Neoplasias Gástricas/metabolismo , Neoplasias Gástricas/patologia , Taxa de Sobrevida , Tetraspanina 29 , Versicanas/metabolismo
7.
J Clin Pharmacol ; 51(7): 1079-86, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-20663999

RESUMO

The preventive effects of lansoprazole and famotidine on low-dose aspirin-induced gastric mucosal injury in relation to gastric acidity were compared in healthy Japanese volunteers. Fifteen Helicobacter pylori-negative volunteers with different CYP2C19 genotypes were randomly administered aspirin 100 mg, aspirin plus famotidine 20 mg twice daily, or aspirin plus lansoprazole 15 mg once daily for 7 days each in a crossover fashion. Gastroscopy for the evaluation of mucosal injury based on modified Lanza score (MLS) and 24-hour intragastric pH monitoring were performed on day 7 of each regimen. Aspirin induced gastric mucosal injury (median MLS = 3). Lansoprazole significantly decreased MLS to 0, which was significantly lower than that by famotidine (MLS = 1) (P < .05). Medians of pH 3 holding time and mean 24-hour pH values with the lansoprazole regimen were significantly higher than those with famotidine (P < .05). No significant differences in MLS were observed among the different CYP2C19 genotype groups in any of the treatment regimens. In this 7-day study, lansoprazole appeared to be more protective than famotidine against low-dose aspirin-induced mucosal injury but a larger well-controlled study is necessary to establish a definitive clinical benefit.


Assuntos
2-Piridinilmetilsulfinilbenzimidazóis/uso terapêutico , Antiulcerosos/uso terapêutico , Famotidina/uso terapêutico , Mucosa Gástrica/efeitos dos fármacos , Antagonistas dos Receptores H2 da Histamina/uso terapêutico , Inibidores da Bomba de Prótons , Úlcera Gástrica/prevenção & controle , 2-Piridinilmetilsulfinilbenzimidazóis/administração & dosagem , Adulto , Anti-Inflamatórios não Esteroides/administração & dosagem , Anti-Inflamatórios não Esteroides/toxicidade , Antiulcerosos/administração & dosagem , Hidrocarboneto de Aril Hidroxilases/genética , Aspirina/administração & dosagem , Aspirina/toxicidade , Estudos Cross-Over , Citocromo P-450 CYP2C19 , Famotidina/administração & dosagem , Feminino , Determinação da Acidez Gástrica , Mucosa Gástrica/patologia , Genótipo , Antagonistas dos Receptores H2 da Histamina/administração & dosagem , Humanos , Japão , Lansoprazol , Masculino , Índice de Gravidade de Doença , Úlcera Gástrica/induzido quimicamente , Úlcera Gástrica/genética , Úlcera Gástrica/patologia , Adulto Jovem
8.
J Clin Pharmacol ; 50(3): 320-30, 2010 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19940233

RESUMO

Aspirin is used widely as an antithrombotic drug for the prevention of cardiovascular and cerebrovascular events. Although aspirin increases the risk for gastrointestinal mucosal injury, the effect on esophageal mucosa is unclear. This study investigates whether aspirin induces esophageal mucosal injury and whether a proton-pump inhibitor can prevent such injury in relation to CYP2C19 genotypes. Fifteen healthy Japanese volunteers are dosed for 7 days in a 5-way randomly crossover trial: placebo, aspirin 100 mg, rabeprazole 10 mg, and aspirin 100 mg plus rabeprazole 10 mg either once daily or 4 times per day. All subjects undergo endoscopy and 24-hour intragastric pH monitoring on day 7. With the aspirin regimen, esophageal mucosal disorders occur in 7 patients (46.7%) (5, grade M; 2, grade A). The median 24-hour pH differs significantly among subjects who develop grade M or A gastroesophageal reflux disease and those who do not develop gastroesophageal reflux disease; the median pH in grade A gastroesophageal reflux disease is significantly lower (1.5 [range, 1.1-1.9]) than that in patients without gastroesophageal reflux disease (5.6 [range, 0.8-8.4], P = .04). Rabeprazole significantly inhibits acid secretion irrespective of CYP2C19 genotypes and decreases the incidence of aspirin-related esophageal injury and symptoms according to increasing pH value. Aspirin induces esophageal mucosal injury in an acid-dependent manner. Concomitant proton-pump inhibitor therapy may prevent advanced effects of low-dose aspirin.


Assuntos
2-Piridinilmetilsulfinilbenzimidazóis/uso terapêutico , Anti-Inflamatórios não Esteroides/efeitos adversos , Antiulcerosos/uso terapêutico , Aspirina/efeitos adversos , Esofagite Péptica/induzido quimicamente , Esofagite Péptica/prevenção & controle , Mucosa Gástrica/efeitos dos fármacos , Refluxo Gastroesofágico/induzido quimicamente , Refluxo Gastroesofágico/prevenção & controle , Inibidores da Agregação Plaquetária/efeitos adversos , 2-Piridinilmetilsulfinilbenzimidazóis/administração & dosagem , Administração Oral , Anti-Inflamatórios não Esteroides/administração & dosagem , Antiulcerosos/administração & dosagem , Hidrocarboneto de Aril Hidroxilases/genética , Povo Asiático , Aspirina/administração & dosagem , Estudos Cross-Over , Citocromo P-450 CYP2C19 , DNA , Relação Dose-Resposta a Droga , Esquema de Medicação , Quimioterapia Combinada , Monitoramento do pH Esofágico , Esofagite Péptica/fisiopatologia , Esofagoscopia , Feminino , Mucosa Gástrica/metabolismo , Refluxo Gastroesofágico/fisiopatologia , Genótipo , Azia/induzido quimicamente , Azia/prevenção & controle , Humanos , Japão , Masculino , Mutação , Inibidores da Agregação Plaquetária/administração & dosagem , Rabeprazol , Adulto Jovem
9.
Dig Dis Sci ; 55(6): 1627-36, 2010 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19672708

RESUMO

BACKGROUND AND AIMS: Gastric acid plays an important role in the pathogenesis of gastric mucosal lesions. We investigated whether aspirin-induced gastric mucosal injury might have any association with the intragastric pH. MATERIALS AND METHODS: Fifteen healthy, Helicobacter pylori-negative volunteers randomly underwent the four different 7-day regimens: (1) aspirin 100 mg, (2) rabeprazole 10 mg, (3) aspirin 100 mg + rabeprazole 10 mg, and (4) aspirin 100 mg + rabeprazole 40 mg. Gastric mucosal injury based on the modified Lanza score (MLS), 24-h intragastric pH, and histopathology of gastric mucosa were evaluated prior to the start and on day 7 of each regimen. RESULTS: The median MLSs were 0 in the baseline and the rabeprazole 10 mg regimen. The median MLS in the aspirin regimen was 3, while those in both aspirin + rabeprazole 10 mg and aspirin + rabeprazole 40 mg regimens were 0. Rabeprazole significantly prevented the gastric mucosal injury by aspirin (P = 0.001 for rabeprazole 10 mg and P = 0.005 for rabeprazole 40 mg). The MLSs were negatively correlated with the 24-h intragastric pH (P = -0.711, < 0.001), whereas aspirin had no effect on the intragastric pH. Aspirin expanded the mean diameter of the microvessels of the gastric mucosa, which, in turn, was negatively correlated with the intragastric pH. CONCLUSIONS: Aspirin might induce gastric mucosal injury by affecting the mucosal microvessels in an acid-dependent manner. Sustained maintenance of the intragastric pH at an elevated value is necessary to prevent gastric mucosal damage induced by aspirin.


Assuntos
2-Piridinilmetilsulfinilbenzimidazóis/administração & dosagem , Anti-Inflamatórios não Esteroides/efeitos adversos , Aspirina/efeitos adversos , Ácido Gástrico/metabolismo , Mucosa Gástrica/efeitos dos fármacos , Inibidores da Bomba de Prótons/administração & dosagem , Úlcera Gástrica/prevenção & controle , 2-Piridinilmetilsulfinilbenzimidazóis/metabolismo , Anti-Inflamatórios não Esteroides/administração & dosagem , Hidrocarboneto de Aril Hidroxilases/genética , Hidrocarboneto de Aril Hidroxilases/metabolismo , Aspirina/administração & dosagem , Biópsia , Citocromo P-450 CYP2C19 , Feminino , Determinação da Acidez Gástrica , Mucosa Gástrica/metabolismo , Mucosa Gástrica/patologia , Gastroscopia , Genótipo , Humanos , Concentração de Íons de Hidrogênio , Masculino , Fenótipo , Inibidores da Bomba de Prótons/metabolismo , Rabeprazol , Índice de Gravidade de Doença , Úlcera Gástrica/induzido quimicamente , Úlcera Gástrica/metabolismo , Úlcera Gástrica/patologia , Adulto Jovem
10.
Surg Today ; 39(12): 1046-53, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19997799

RESUMO

PURPOSE: Combination therapy using antiangiogenic and cytotoxic agents is a useful strategy for advanced cancer, but the mechanism has not yet been elucidated. Moreover, there is a persistent paradox that destroying tumor vasculature with antiangiogenic agents disturbs the delivery of cytotoxic agents. It has been hypothesized that antiangiogenic agents can lead to normalization of tumor vessels that are structurally and functionally abnormal. The normalization means enhancing the deliver of cytotoxic agents. Our purpose was to investigate whether TSU68, a multiple receptor tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor-2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), would induce the normalization of tumor vessels. METHODS: TSU68 was administered for 7 days to mice with xenografted tumors. Tumors of interstitial fluid pressure (IFP) were measured before and after administration of agents. Immunofluorescence double staining for CD31 and alpha-SMA was performed, and a medical video endoscopy system with narrowband illumination (NBI) was used to visualize the vascular pattern. RESULTS: TSU68 treatment decreased IFP significantly. Immunofluorescence double staining showed a significant increase in the fraction of pericyte coverage in the TSU68-treated group. NBI endoscopy showed that many tumor vessels in TSU68-treated mice were pruned and the diameters of remaining vessels were reduced. CONCLUSION: The data supported our hypothesis of tumor vascular normalization by the antiangiogenic agent TSU68.


Assuntos
Inibidores da Angiogênese/farmacologia , Colo/irrigação sanguínea , Neoplasias do Colo/tratamento farmacológico , Indóis/farmacologia , Neovascularização Patológica/prevenção & controle , Neovascularização Fisiológica/fisiologia , Propionatos/farmacologia , Animais , Colo/patologia , Neoplasias do Colo/patologia , Modelos Animais de Doenças , Sistemas de Liberação de Medicamentos/métodos , Humanos , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Neovascularização Fisiológica/efeitos dos fármacos , Oxindóis , Pirróis , Receptores de Fatores de Crescimento de Fibroblastos/efeitos dos fármacos , Receptores de Fatores de Crescimento de Fibroblastos/metabolismo , Receptores do Fator de Crescimento Derivado de Plaquetas/efeitos dos fármacos , Receptores do Fator de Crescimento Derivado de Plaquetas/metabolismo , Sensibilidade e Especificidade , Transplante Heterólogo , Receptor 2 de Fatores de Crescimento do Endotélio Vascular/efeitos dos fármacos , Receptor 2 de Fatores de Crescimento do Endotélio Vascular/metabolismo , Ensaios Antitumorais Modelo de Xenoenxerto
11.
J Neurochem ; 109(2): 393-402, 2009 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-19200342

RESUMO

In order to examine the possible involvements of Ca(2+)/calmodulin-dependent protein kinases (CaM kinases) in the regulation of ribosomal functions, we tested the phosphorylation of rat ribosomal protein S19 (RPS19) by various CaM kinases in vitro. We found that CaM kinase Ialpha, but not CaM kinase Ibeta1, Ibeta2, II, or IV, robustly phosphorylated RPS19. From the consensus phosphorylation site sequence, Ser59, Ser90, and Thr124 were likely to be phosphorylated; therefore, we mutated each amino acid to alanine and found that the mutation of Ser59 to alanine strongly attenuated phosphorylation by CaM kinase Ialpha, suggesting that Ser59 was a major phosphorylation site. Furthermore, we produced a specific antibody against RPS19 phosphorylated at Ser59, and found that Ser59 was phosphorylated both in GT1-7 cells and rat brain. Phosphorylation of RPS19 in GT1-7 cells was inhibited by KN93, an inhibitor of CaM kinases. Immunoblot analysis after subcellular fractionation of rat brain demonstrated that phosphorylated RPS19 was present in 80S ribosomes. Phosphorylation of RPS19 by CaM kinase Ialpha augmented the interaction of RPS19 with the previously identified S19 binding protein. These results suggest that CaM kinase Ialpha regulates the functions of RPS19 through phosphorylation of Ser59.


Assuntos
Proteína Quinase Tipo 1 Dependente de Cálcio-Calmodulina/metabolismo , Proteínas de Drosophila/metabolismo , Proteínas Ribossômicas/metabolismo , Serina/metabolismo , Animais , Linhagem Celular Transformada , Fosforilação , Subunidades Proteicas/metabolismo , Ratos
12.
Cancer Res ; 68(23): 9754-62, 2008 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-19047154

RESUMO

The aim of this study was to investigate the inhibitory effect of TSU68 [(Z)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid; SU6668], an inhibitor of vascular endothelial growth factor receptor 2, platelet-derived growth factor receptor beta, and fibroblast growth factor receptor 1 (FGFR1), on colon cancer liver metastasis, and to test the hypothesis that TSU68 modulates the microenvironment in the liver before the formation of metastasis. First, we implanted the highly metastatic human colon cancer TK-4 orthotopically into the cecal walls of nude mice, followed by twice-daily administration of TSU68 (400 mg/kg/d) or vehicle. Five weeks of treatment with TSU68 significantly inhibited liver metastasis compared with the control group (P<0.001). Next, we analyzed the gene expression profile in premetastatic liver using microarrays. Microarray and quantitative reverse transcription-PCR analysis showed that mRNA levels for the chemokine CXCL1 were significantly increased in tumor-bearing mice compared with non-tumor-bearing mice. Moreover, CXCL1 expression was significantly decreased by TSU68 treatment. CXCR2 expression was detected predominantly on tumor cells in orthotopic tumors compared with ectopic tumors. The number of migrating neutrophils in premetastatic liver was significantly decreased in the TSU68-treated group (P<0.001). The amount of interleukin-12 (IL-12) p40 in the portal vein was significantly decreased by TSU68 (P=0.02). Blockade of both CXCR2 and IL-12 p40 with a neutralizing antibody significantly inhibited liver metastasis. These results suggest that the CXCL1/CXCR2 axis is important in cancer metastasis and that TSU68 may modulate the premetastatic niche in the target organ through suppression of the inflammatory response, which might be an alternative mechanism used by antiangiogenic agents.


Assuntos
Neoplasias do Colo/tratamento farmacológico , Neoplasias do Colo/patologia , Indóis/farmacologia , Neoplasias Hepáticas Experimentais/prevenção & controle , Neoplasias Hepáticas Experimentais/secundário , Propionatos/farmacologia , Animais , Movimento Celular/imunologia , Quimiocina CXCL1/biossíntese , Quimiocina CXCL1/genética , Neoplasias do Colo/genética , Neoplasias do Colo/imunologia , Perfilação da Expressão Gênica , Humanos , Subunidade p40 da Interleucina-12/antagonistas & inibidores , Subunidade p40 da Interleucina-12/imunologia , Fígado/irrigação sanguínea , Fígado/fisiopatologia , Neoplasias Hepáticas Experimentais/genética , Neoplasias Hepáticas Experimentais/imunologia , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Neutrófilos/imunologia , Neutrófilos/patologia , Análise de Sequência com Séries de Oligonucleotídeos , Oxindóis , Pirróis , RNA Mensageiro/biossíntese , RNA Mensageiro/genética , Receptores de Interleucina-8B/antagonistas & inibidores , Receptores de Interleucina-8B/biossíntese , Receptores de Interleucina-8B/genética , Ensaios Antitumorais Modelo de Xenoenxerto
13.
Anticancer Res ; 28(2A): 693-8, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18507009

RESUMO

Antitumor effects of plasminogen activator (PA) inhibitors (PAls) were analyzed in a mouse model of human colon cancer xenografts. Either recombinant PA inhibitor-1 (rPAI-1) or inhibitor-2 (rPAI-2) was injected intraperitoneally to nude mice bearing human colon cancer xenografts for 6 weeks. Primary tumors in rPAI-2-treated group were smaller (0.45 +/- 0.13 g, n = 16) than in the other two groups (control: 0.73 +/- 0.24 g, n = 15; rPAI-1: 0.62 +/- 0.29 g, n = 19). Primary tumors in the rPAI-2-treated group exhibited less mature ductal structures and were significantly smaller. The apoptotic index was higher in the rPAI-2-treated group (4.64 +/- 2.12%) than in the other groups (control: 1.94 +/- 0.82%; rPAI-1: 2.08 +/- 1.07%). Liver metastasis was less frequent in the rPAI-1 (5/19) and rPAI-2-treated groups (1/16) than in the control group (14/15). PAI-2 more effectively suppressed tumor metastasis and progression, probably by inducing apoptosis; some different unknown mechanism may cause the difference in both antitumor effect and the histological findings. This may indicate the therapeutic potential of these PAls in malignant patients.


Assuntos
Apoptose/efeitos dos fármacos , Neoplasias do Colo/tratamento farmacológico , Neoplasias Hepáticas/secundário , Inibidor 2 de Ativador de Plasminogênio/farmacologia , Animais , Avaliação de Medicamentos , Humanos , Infusões Parenterais , Neoplasias Hepáticas/prevenção & controle , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Inibidor 2 de Ativador de Plasminogênio/administração & dosagem , Proteínas Recombinantes/farmacologia , Ensaios Antitumorais Modelo de Xenoenxerto
14.
Chem Pharm Bull (Tokyo) ; 56(5): 692-4, 2008 May.
Artigo em Inglês | MEDLINE | ID: mdl-18451560

RESUMO

Silver loaded zeolite (Ag-Z) was previously found to have effective bactericidal activity against Escherichia coli. To understand the mechanisms of bactericidal activity of Ag-Z, role of light irradiation was focused and investigated in this study. In this study, we focused on light irradiation. Antibacterial assay and spectroscopic study revealed that light irradiation enabled Ag-Z to reduce dioxygen to form a reactive oxygen species, which led to bactericidal activity. These results indicate that the onset of bactericidal activity can be controlled by light irradiation.


Assuntos
Antibacterianos/farmacologia , Antibacterianos/efeitos da radiação , Bactérias/efeitos dos fármacos , Bactérias/efeitos da radiação , Prata/farmacologia , Prata/efeitos da radiação , Zeolitas/farmacologia , Zeolitas/efeitos da radiação , Antibacterianos/química , Bactérias/enzimologia , Contagem de Colônia Microbiana , Citocromos c/metabolismo , Espectroscopia de Ressonância de Spin Eletrônica , Escherichia coli/efeitos dos fármacos , Escherichia coli/efeitos da radiação , Luz , Oxigênio/química , Oxigênio/efeitos da radiação , Espécies Reativas de Oxigênio/metabolismo , Prata/química , Espectrofotometria Ultravioleta , Zeolitas/química
15.
J Gastroenterol ; 43(4): 283-90, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18458844

RESUMO

BACKGROUND: Gastric cancer is one of the most common cancers in Japan. The use of endoscopy is increasing, along with the number of histological examinations of specimens obtained by endoscopy. However, it takes several days to reach a diagnosis, which increases the medical expense. Raman spectroscopy is one of the available optical techniques, and the Raman spectrum for each molecule and tissue is characteristic and specific. The present study investigated whether Raman spectroscopy can be used to diagnose gastric cancer. METHODS: A total of 251 fresh biopsy specimens of gastric carcinoma and non-neoplastic mucosa were obtained from 49 gastric cancer patients at endoscopy. Without any pretreatment, the fresh specimens were measured with a near-infrared multichannel Raman spectroscopic system with an excitation wavelength of 1064 nm, and Raman spectra specific for the specimens were obtained. A principal component analysis (PCA) was performed to distinguish gastric cancer and non-neoplastic tissue, and a discriminant analysis was used to evaluate the accuracy of the gastric cancer diagnosis. RESULTS: The Raman spectra for cancer specimens differed from those for non-neoplastic specimens, especially at around 1644 cm(-1). Sensitivity was 66%, specificity was 73%, and accuracy was 70%. The accuracy of diagnosis using the single Raman scattering intensity at 1644 cm(-1) was 70%, consistent with the PCA result. CONCLUSIONS: The present results indicate that near-infrared multichannel Raman spectroscopy with a 1064-nm excitation wavelength is useful for gastric cancer diagnosis. Establishment of a Raman diagnostic system for gastric cancer may improve the clinical diagnosis of gastric cancer and be beneficial for patients.


Assuntos
Carcinoma/diagnóstico , Mucosa Gástrica/patologia , Análise Espectral Raman/métodos , Neoplasias Gástricas/diagnóstico , Adulto , Idoso , Idoso de 80 Anos ou mais , Biópsia , Diagnóstico Diferencial , Feminino , Seguimentos , Humanos , Lasers de Estado Sólido , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Sensibilidade e Especificidade
16.
Cancer Sci ; 98(11): 1734-9, 2007 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17894554

RESUMO

The authors have previously reported that loss of heterozygosity (LOH) of the c-kit gene could be responsible for the gain in high proliferative activity in some gastrointestinal stromal tumors (GIST), resulting in enhanced metastatic potential. In the present study, an attempt was made to identify the factors that might predict the postoperative prognosis of patients with metastatic liver GIST. The clinicopathologic or genetic features of resected liver GIST in 14 patients who had undergone a hepatectomy for metachronous liver metastases and who had not received adjuvant imatinib treatment were examined. LOH of the c-kit gene was observed in seven of 12 metastatic liver GIST (58.3%), of which DNA suitable for testing could be extracted. Ten patients had recurrence after hepatectomy and four had none. The median post-recurrent disease-free survival (PRDFS) after hepatectomy was 27.5 months (range 8-104). The tumor-specific PRDFS was examined using clinicopathologic features, c-kit mutation and LOH of the c-kit gene. No single clinicopathologic or genetic finding was significantly associated with PRDFS. However, patients with 'Ki67 labeling index <5% and LOH(-)' had a significantly longer PRDFS than those with 'Ki67 >/=5% or LOH(+)' (P = 0.032), and there was no correlation between the presence of LOH of the c-kit gene and the Ki67 labeling index. LOH of the c-kit gene in metastatic liver seems to be a common event, and LOH of the c-kit gene in resected liver GIST may be a helpful factor in the prediction of the post-recurrent prognosis of patients with liver metastasis.


Assuntos
Tumores do Estroma Gastrointestinal/genética , Tumores do Estroma Gastrointestinal/cirurgia , Hepatectomia , Neoplasias Hepáticas/genética , Neoplasias Hepáticas/cirurgia , Perda de Heterozigosidade , Proteínas Proto-Oncogênicas c-kit/genética , Idoso , Análise Mutacional de DNA , DNA de Neoplasias/genética , DNA de Neoplasias/isolamento & purificação , Éxons , Feminino , Tumores do Estroma Gastrointestinal/patologia , Humanos , Imuno-Histoquímica , Neoplasias Hepáticas/patologia , Masculino , Repetições de Microssatélites , Pessoa de Meia-Idade , Metástase Neoplásica , Reação em Cadeia da Polimerase , Prognóstico , Resultado do Tratamento
17.
Cancer Res ; 66(24): 11623-31, 2006 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-17178856

RESUMO

A reduced expression level of the cyclin-dependent kinase inhibitor p27(Kip1) is associated with increased tumor malignancy and poor prognosis in individuals with various types of cancer. To investigate the basis for this relation, we applied microarray analysis to screen for genes differentially expressed between p27(+/-) and parental (p27(+/+)) HCT116 human colon carcinoma cells. Expression of the gene for G protein-coupled receptor 48 (GPR48) was increased in the p27(+/-) cells. Forced expression of GPR48 increased both in vitro invasive activity and lung metastasis potency of HCT116 cells. In contrast, depletion of endogenous GPR48 by RNA interference reduced the invasive potential of HeLa and Lewis lung carcinoma cells not only in vitro but also in vivo. Moreover, GPR48 expression was significantly associated with lymph node metastasis and inversely correlated with p27 expression in human colon carcinomas. GPR48 may thus play an important role in invasiveness and metastasis of carcinoma and might therefore represent a potential prognostic marker or therapeutic target.


Assuntos
Regulação Neoplásica da Expressão Gênica , Peptídeos e Proteínas de Sinalização Intracelular/genética , Invasividade Neoplásica/genética , Receptores Acoplados a Proteínas G/genética , Animais , Linhagem Celular , Linhagem Celular Tumoral , Neoplasias do Colo , Inibidor de Quinase Dependente de Ciclina p27 , Primers do DNA , Fibroblastos/fisiologia , Genes Reporter , Células HeLa , Humanos , Luciferases/genética , Camundongos , Metástase Neoplásica/genética , Análise de Sequência com Séries de Oligonucleotídeos , Antígeno Nuclear de Célula em Proliferação/genética , Interferência de RNA , Reação em Cadeia da Polimerase Via Transcriptase Reversa
18.
Nihon Shokakibyo Gakkai Zasshi ; 103(9): 1055-60, 2006 Sep.
Artigo em Japonês | MEDLINE | ID: mdl-16953103

RESUMO

A 58-year-old Japanese man underwent partial gastrectomy in 1991 for a tumor showing extra-gastric growth measuring 18 x 16.5 x 8.8 cm in size. An immunohistochemical study yielded a diagnosis of gastric GIST with few mitoses. In 2004, abdominal CT showed a solitary liver metastasis without extrahepatic recurrence and right hepatic lobectomy was performed. No adjuvant treatment has been done and he is alive without recurrence 1 year after the hepatectomy. Long term follow-up of more than 10 years is required after resection of primary tumors if they are diagnosed as high risk GISTs with few mitoses.


Assuntos
Gastrectomia , Tumores do Estroma Gastrointestinal/secundário , Tumores do Estroma Gastrointestinal/cirurgia , Neoplasias Hepáticas/secundário , Neoplasias Gástricas/patologia , Neoplasias Gástricas/cirurgia , Hepatectomia , Humanos , Neoplasias Hepáticas/cirurgia , Masculino , Pessoa de Meia-Idade , Período Pós-Operatório , Fatores de Tempo
19.
World J Gastroenterol ; 12(21): 3393-9, 2006 Jun 07.
Artigo em Inglês | MEDLINE | ID: mdl-16733857

RESUMO

AIM: To investigate the relationship between ulcerative colitis (UC) clinical activity index (CAI) and circulating levels of IL-1ra, IL-10, IL-6 and IL-18. METHODS: Blood levels of IL-1ra, IL-10, IL-6 and IL-18 were measured in 31 patients with active UC, the mean CAI was 11.1, ranging from 5-25; and 12 healthy individuals as controls. Patients were given granulocyte and monocyte adsorptive apheresis (GMA) with Adacolumn. Leucocytes which bear the FcgammaR and complement receptors were adsorbed to the column leucocytapheresis carriers. Each patient could receive up to 11 GMA sessions over 8 wk. RESULTS: We found strong correlations between CAI and IL-10 (r = 0.827, P < 0.001), IL-6 (r = 0.785, P < 0.001) and IL-18 (r = 0.791, P < 0.001). IL-1ra was not correlated with CAI. Following GMA therapy, 24 of the 31 patients achieved remission and the levels of all 4 cytokines fell to the levels in healthy controls. Further, blood levels of IL-1ra and IL-10 increased at the column outflow and inflow at 60 min suggesting release from leucocytes that adhered to the carriers.


Assuntos
Colite Ulcerativa/sangue , Colite Ulcerativa/imunologia , Citocinas/sangue , Interleucinas/sangue , Leucaférese/métodos , Adolescente , Adulto , Contagem de Células Sanguíneas , Colite Ulcerativa/terapia , Citocinas/fisiologia , Feminino , Granulócitos/patologia , Granulócitos/fisiologia , Humanos , Inflamação/sangue , Inflamação/fisiopatologia , Macrófagos/patologia , Macrófagos/fisiologia , Masculino , Pessoa de Meia-Idade , Monócitos/patologia , Monócitos/fisiologia , Índice de Gravidade de Doença
20.
Cancer Sci ; 97(2): 127-32, 2006 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-16441423

RESUMO

Metastatic gastrointestinal stromal tumors (GIST) have an extremely poor prognosis; however, their immunohistochemical and genetic features have not been assessed satisfactorily and the mechanisms responsible for their high malignant potential remain unclear. We examined the immunohistochemical differences between gastric GIST and metastatic lesions in the liver of four patients who had undergone a postgastrectomy hepatectomy for metachronous liver metastases. We also carried out genetic analysis of the tumors in three of the four cases. In all cases, the immunoreactivity profiles, including KIT (CD117), CD34, smooth muscle actin (SMA), desmin, S-100 and vimentin, were similar between the gastric and metastatic tumors, but the Ki67 labeling index in the metastatic GIST was higher than that of the primary GIST. Interestingly, in the case who had received neoadjuvant imatinib therapy before gastrectomy, its therapeutic effect was observed in most of the primary lesion, with the exception of a specific small area with high cellularity. Genetic analysis revealed no acquired mutations in the c-kit or PDGFRA genes in the metastatic lesions in any of the patients, but loss of heterozygosity (LOH) of the c-kit gene was observed mainly in the metastatic tumors in two of the three cases. Furthermore, in the case of neoadjuvant imatinib therapy, LOH of the c-kit gene was shown in the high cellularity area in the primary lesion and metastatic liver GIST. It is suggested that LOH of the c-kit gene is an important event that leads to imatinib resistance and metastatic progression of GIST. In conclusion, both gastric and metastatic GIST had almost the same immunohistochemical features, except for their proliferative activity, and LOH of the c-kit gene played an important role in the process of liver metastasis.


Assuntos
Tumores do Estroma Gastrointestinal/genética , Neoplasias Hepáticas/genética , Proteínas de Neoplasias/metabolismo , Proteínas Proto-Oncogênicas c-kit/genética , Neoplasias Gástricas/genética , Idoso , Sequência de Aminoácidos , Antineoplásicos/uso terapêutico , Benzamidas , Feminino , Tumores do Estroma Gastrointestinal/metabolismo , Tumores do Estroma Gastrointestinal/secundário , Humanos , Mesilato de Imatinib , Técnicas Imunoenzimáticas , Neoplasias Hepáticas/metabolismo , Neoplasias Hepáticas/secundário , Perda de Heterozigosidade , Masculino , Repetições de Microssatélites , Pessoa de Meia-Idade , Dados de Sequência Molecular , Piperazinas/uso terapêutico , Pirimidinas/uso terapêutico , Homologia de Sequência de Aminoácidos , Neoplasias Gástricas/metabolismo , Neoplasias Gástricas/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA